“The allegations in the complaint highlight serious violations of securities laws. If proven true, Humacyte's alleged failure to disclose material information to investors is unacceptable,” said Reed ...

Event: Piper Sandler 36th Annual Healthcare Conference Location: The Lotte New York Palace, NY Presentation: Thursday, December 5, 8:00 a.m. EST Webcast: https://event.webcasts.com/ A replay will be ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers ...

DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the Humacyte V005 trauma clinical trial. “The ATEV is perfectly sized to ...